keyword
MENU ▼
Read by QxMD icon Read
search

Value based pricing

keyword
https://www.readbyqxmd.com/read/27924754/relevance-of-randomised-controlled-trials-in-oncology
#1
REVIEW
Ian F Tannock, Eitan Amir, Christopher M Booth, Saroj Niraula, Alberto Ocana, Bostjan Seruga, Arnoud J Templeton, Francisco Vera-Badillo
Well-designed randomised controlled trials (RCTs) can prevent bias in the comparison of treatments and provide a sound basis for changes in clinical practice. However, the design and reporting of many RCTs can render their results of little relevance to clinical practice. In this Personal View, we discuss the limitations of RCT data and suggest some ways to improve the clinical relevance of RCTs in the everyday management of patients with cancer. RCTs should ask questions of clinical rather than commercial interest, avoid non-validated surrogate endpoints in registration trials, and have entry criteria that allow inclusion of all patients who are fit to receive treatment...
December 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27921381/cost-analysis-of-the-treatment-of-severe-acute-malnutrition-in-west-africa
#2
Sheila Isanaka, Nicolas A Menzies, Jessica Sayyad, Mudasiru Ayoola, Rebecca F Grais, Stéphane Doyon
We present an updated cost analysis to provide new estimates of the cost of providing community-based treatment for severe acute malnutrition, including expenditure shares for major cost categories. We calculated total and per child costs from a provider perspective. We categorized costs into three main activities (outpatient treatment, inpatient treatment, and management/administration) and four cost categories within each activity (personnel; therapeutic food; medical supplies; and infrastructure and logistical support)...
December 5, 2016: Maternal & Child Nutrition
https://www.readbyqxmd.com/read/27919563/waste-management-in-the-meat-processing-industry-conversion-of-paunch-and-daf-sludge-into-solid-fuel
#3
Ihsan Hamawand, Pam Pittaway, Larry Lewis, Sayan Chakrabarty, Justin Caldwell, Jochen Eberhard, Arpita Chakraborty
This article addresses the novel dewatering process of immersion-frying of paunch and dissolved air flotation (DAF) sludge to produce high energy pellets. Literature have been analysed to address the feasibility of replacing conventional boiler fuel at meat processing facilities with high energy paunch-DAF sludge pellets (capsules). The value proposition of pelleting and frying this mixture into energy pellets is based on a Cost-Benefit Analysis (CBA). The CBA is based on information derived from the literature and consultation with the Australian Meat Processing Industry...
December 2, 2016: Waste Management
https://www.readbyqxmd.com/read/27918774/cost-effectiveness-of-prophylactic-moisturization-for-atopic-dermatitis
#4
Shuai Xu, Supriya Immaneni, Gordon B Hazen, Jonathan I Silverberg, Amy S Paller, Peter A Lio
Importance: Emerging evidence suggests that the use of moisturizers on newborns and infants (ie, from birth to 6 months of age) is potentially helpful in preventing the development of atopic dermatitis. Objective: To investigate the cost-effectiveness of using a daily moisturizer as prevention against atopic dermatitis among high-risk newborns. Design, Setting, and Participants: In a cost-effectiveness analysis, the average cost of total-body moisturization using 7 common moisturizers from birth to 6 months of age was determined for male and female infants...
December 5, 2016: JAMA Pediatrics
https://www.readbyqxmd.com/read/27913940/cost-analysis-and-cost-benefit-analysis-of-a-medication-review-with-follow-up-service-in-aged-polypharmacy-patients
#5
Amaia Malet-Larrea, Estíbaliz Goyenechea, Miguel A Gastelurrutia, Begoña Calvo, Victoria García-Cárdenas, Juan M Cabases, Aránzazu Noain, Fernando Martínez-Martínez, Daniel Sabater-Hernández, Shalom I Benrimoj
BACKGROUND: Drug related problems have a significant clinical and economic burden on patients and the healthcare system. Medication review with follow-up (MRF) is a professional pharmacy service aimed at improving patient's health outcomes through an optimization of the medication. OBJECTIVE: To ascertain the economic impact of the MRF service provided in community pharmacies to aged polypharmacy patients comparing MRF with usual care, by undertaking a cost analysis and a cost-benefit analysis...
December 2, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27905819/mothers-preferences-regarding-new-combination-vaccines-for-their-children-in-japan-2014
#6
Aiko Shono, Masahide Kondo
A number of new vaccines to prevent childhood diseases have been introduced globally over the last few decades. Only four combination vaccines are currently available in Japan, DTaP/sIPV, DTaP, DT, and MR, leading to complex infant vaccine scheduling. This study aims to investigate mothers' preferences with respect to combination vaccines for their children, should new combination vaccines become available that have not yet been launched in Japan or that will be developed in the future. We conducted a web-based, cross-sectional survey of 1,243 mothers who had at least one child between 2 months and 3 years of age...
December 1, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27903217/rational-drug-discovery-of-hcv-helicase-inhibitor-improved-docking-accuracy-with-multiple-seedings-of-autodock-vina-and-in-situ-minimization
#7
SeeKhai Lim, Rozana Othman, Rohana Yusof, ChoonHan Heh
BACKGROUND: Hepatitis C is a significant cause for end-stage liver diseases and liver transplantation which affects approximate 3% of the global populations. Despite the present of several direct antiviral agents in the treatment of hepatitis C, the standard treatment for HCV is accompanied by several drawbacks such as adverse side effects, high pricing of medications and the rapid emerging rate of resistant HCV variants. OBJECTIVES: To discover potential inhibitors for HCV helicase through an optimized in silico approach...
November 30, 2016: Current Computer-aided Drug Design
https://www.readbyqxmd.com/read/27867559/impact-of-anticancer-drugs-price-cut-on-physician-s-prescription-choices-on-first-line-chemotherapy-regimens-and-health-expenditure-for-advanced-non-small-cell-lung-cancer-in-china
#8
Bei Li, Mei-Ying Li, Luan-Luan Sun, Jian Wang, Yan-Qing Zheng, Jing Hao
BACKGROUND: Increases in insurance coverage and price cut of drugs are two important measures to make health care more accessible and affordable. As far as we know, this was the first study to explore the impact of anticancer drug price cut on health expenses and oncologist's prescription decisions in China. METHODS: The 511 non-small cell lung cancer (NSCLC) patients were recruited from Qilu Affiliated Hospital of Shandong University from January 1, 2003 to December 31, 2010...
October 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27858569/treatment-prices-at-the-point-of-care-in-a-clinical-oncology-service-pilot-project
#9
Nora B Henrikson, Rebecca W Lau, Leah Tuzzio, Matthew Christianson, Thanh-Hien Phan, Eric Chen
PURPOSE: Patients with cancer increasingly wish to discuss cancer care costs with clinicians. We aimed to improve clinician access to treatment prices. METHODS: We developed a pilot tool and accompanying workflow for four oncology clinics in an integrated care system. The online tool included 50 printable worksheets for cancer treatment protocols and was accessible directly from the electronic health record. Each sheet included codes and prices for all drugs and services for one treatment cycle in patient-friendly language...
October 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27857827/perceptions-and-factors-affecting-pharmaceutical-market-access-results-from-a-literature-review-and-survey-of-stakeholders-in-different-settings
#10
Semukaya Sendyona, Isaac Odeyemi, Khaled Maman
BACKGROUND: A change in the pharmaceutical environment has occurred from previously only needing to convince regulators of a product's safety and efficacy to obtain marketing authorisation to now needing to satisfy the value perceptions of other stakeholders, including payers, to attain market access for products. There is thus the need to understand the concept of market access that may be defined as 'the process that ensures the development and commercial availability of pharmaceutical products with appropriate value propositions, leading to their prescribing and to successful uptake decisions by payers and patients, with the ultimate goal of achieving profitability and best patient outcomes'...
2016: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/27828732/economics-of-ramucirumab-for-metastatic-colorectal-cancer
#11
Simon B Zeichner, Christine G Kohn, Daniel A Goldstein
Introduction Despite its FDA approval and incorporation into the National Comprehensive Cancer Network (NCCN) treatment guidelines, ramucirumab (RAM) is associated with a drug acquisition cost that is substantially higher than other approved options. Given its substantial cost, the presence of a viable alternative treatment option, and its minimal survival improvement, the usefulness of RAM in clinical practice has been called into question. Areas covered In this paper, we outline the cost, benefits, and economic implications of RAM from a US perspective, as it is used in the treatment of mCRC...
November 9, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27822961/the-cost-effectiveness-of-disease-modifying-therapies-for-the-treatment-of-relapsing-remitting-multiple-sclerosis
#12
Duygu Bozkaya, Terrie Livingston, Kristen Migliaccio-Walle, Tanner Odom
BACKGROUND: The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal value, given benefit-risk profiles and costs. AIMS: To compare the cost-effectiveness of current DMTs for patients with RRMS in the US. MATERIALS AND METHODS: A Markov model predicting RRMS course following initiation of a DMT was created comparing outcomes (e...
November 21, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27817814/exercise-induced-bronchoconstriction-in-athletes-a-qualitative-assessment-of-symptom-perception
#13
Oliver J Price, James H Hull, Les Ansley, Mike Thomas, Caroline Eyles
BACKGROUND: A poor relationship between perceived respiratory symptoms and objective evidence of exercise-induced bronchoconstriction (EIB) in athletes is often reported; however, the reasons for this disconnect remain unclear. The primary aim of this study was to utilise a qualitative-analytical approach to compare respiratory symptoms in athletes with and without objectively confirmed EIB. METHODS: Endurance athletes who had previously undergone bronchoprovocation test screening for EIB were divided into sub-groups, based on the presence or absence of EIB ± heightened self-report of dyspnoea: (i) EIB-Dys- (ii) EIB + Dys+ (iii) EIB + Dys- (iv) EIB-Dys+...
November 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/27802278/projected-impact-of-mexico-s-sugar-sweetened-beverage-tax-policy-on-diabetes-and-cardiovascular-disease-a-modeling-study
#14
Luz Maria Sánchez-Romero, Joanne Penko, Pamela G Coxson, Alicia Fernández, Antoinette Mason, Andrew E Moran, Leticia Ávila-Burgos, Michelle Odden, Simón Barquera, Kirsten Bibbins-Domingo
BACKGROUND: Rates of diabetes in Mexico are among the highest worldwide. In 2014, Mexico instituted a nationwide tax on sugar-sweetened beverages (SSBs) in order to reduce the high level of SSB consumption, a preventable cause of diabetes and cardiovascular disease (CVD). We used an established computer simulation model of CVD and country-specific data on demographics, epidemiology, SSB consumption, and short-term changes in consumption following the SSB tax in order to project potential long-range health and economic impacts of SSB taxation in Mexico...
November 2016: PLoS Medicine
https://www.readbyqxmd.com/read/27798809/a-review-of-us-drug-costs-relevant-to-medicare-medicaid-and-commercial-insurers-post-affordable-care-act-enactment-2010-2016
#15
REVIEW
Jacquelyn McRae, F Randy Vogenberg, Silky Webb Beaty, Elizabeth Mearns, Stefan Varga, Laura Pizzi
Since passage of the Affordable Care Act (ACA) in 2010, US stakeholders are increasingly being held accountable for the value of healthcare services and drugs administered to patients. Pharmacoeconomic analyses offer one method of demonstrating a product's value, yet there is a lack of resources specific to US drug costs relevant to each stakeholder. The aim of this study was to review current US drug costs (post-ACA). A literature review aimed at finding evidence on outpatient prescription drug costs was performed using the following sources: PubMed, governmental agencies, news websites, the Academy of Managed Care Pharmacy (AMCP) website, and Google Scholar...
October 31, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27798808/economic-evaluation-in-duchenne-muscular-dystrophy-model-frameworks-for-cost-effectiveness-analysis
#16
Erik Landfeldt, Lars Alfredsson, Volker Straub, Hanns Lochmüller, Katharine Bushby, Peter Lindgren
BACKGROUND: Several treatments are on the horizon for Duchenne muscular dystrophy (DMD), a terminal orphan disease. In many jurisdictions, decisions regarding pricing and reimbursement of these health technologies comprise evidence of value for money. OBJECTIVE: The objective of this study was to develop a cost-effectiveness model based on the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT), a new rating scale created specifically to measure disease progression in clinical practice and trials and model DMD in economic evaluations, and compare it with two alternative model structures...
October 31, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27795890/pricing-for-a-basket-of-lcds-under-fuzzy-environments
#17
Liang Wu, Jie-Fang Liu, Jun-Tao Wang, Ya-Ming Zhuang
This paper looks at both the prepayment risks of housing mortgage loan credit default swaps (LCDS) as well as the fuzziness and hesitation of investors as regards prepayments by borrowers. It further discusses the first default pricing of a basket of LCDS in a fuzzy environment by using stochastic analysis and triangular intuition-based fuzzy set theory. Through the 'fuzzification' of the sensitivity coefficient in the prepayment intensity, this paper describes the dynamic features of mortgage housing values using the One-factor copula function and concludes with a formula for 'fuzzy' pricing the first default of a basket of LCDS...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27784062/cost-effectiveness-of-bariatric-surgery-in-adolescents-with-obesity
#18
Matthew J Klebanoff, Jagpreet Chhatwal, Jacob D Nudel, Kathleen E Corey, Lee M Kaplan, Chin Hur
Importance: Severe obesity affects 4% to 6% of US youth and is increasing in prevalence. Bariatric surgery for the treatment of adolescents with severe obesity is becoming more common, but data on cost-effectiveness are limited. Objective: To assess the cost-effectiveness of bariatric surgery for adolescents with obesity using recently published results from the Teen-Longitudinal Assessment of Bariatric Surgery study. Design, Setting, and Patients: A state-transition model was constructed to compare 2 strategies: no surgery and bariatric surgery...
October 26, 2016: JAMA Surgery
https://www.readbyqxmd.com/read/27783645/spatial-and-social-media-data-analytics-of-housing-prices-in-shenzhen-china
#19
Chao Wu, Xinyue Ye, Fu Ren, You Wan, Pengfei Ning, Qingyun Du
Housing is among the most pressing issues in urban China and has received considerable scholarly attention. Researchers have primarily concentrated on identifying the factors that influence residential property prices and how such mechanisms function. However, few studies have examined the potential factors that influence housing prices from a big data perspective. In this article, we use a big data perspective to determine the willingness of buyers to pay for various factors. The opinions and geographical preferences of individuals for places can be represented by visit frequencies given different motivations...
2016: PloS One
https://www.readbyqxmd.com/read/27771612/oncology-drug-costs-the-imaginary-crisis
#20
R Turck
Complaints about cancer drug costs are manifold. While there is excess in some cases and a significant financial burden for patients it appears that the outrage is not always well informed. In recent years innovative cancer drugs have improved patient' survival while better maintaining quality of life. Cancer drug costs represent less than 1% of overall healthcare costs, yet it is estimated that 83% of increased cancer survival can be attributed to new treatments. The challenge is to provide those cancer drugs that best address a patient's needs in the most cost-effective manner...
October 22, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
36961
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"